The inhaled mebufotenin candidate, dubbed GH001, was evaluated in the midstage study of 81 patients with treatment-resistant depression. The 40 patients who received GH001 saw an average 15.2 point ...
Depression was assessed using the Patient Health Questionnaire-9 (PHQ-9), a widely used tool for measuring depressive symptoms based on the Diagnostic and Statistical Manual of Mental Disorders ...